A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
Part of paid clinical trials in Los Angeles, California.
- Sponsor
- Vor Biopharma
- Study ID
- NCT06456580
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Generalized Myasthenia Gravis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Telitacicept — BIOLOGICALSubcutaneous injection
- Placebo — DRUGSubcutaneous injection
Study Details
The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of generalized myasthenia gravis.
Key Dates
- Start date
- Jul 17, 2024
- Status verified
- May 2026
- Primary completion
- May 31, 2027
- Completion
- Jan 31, 2029
Study Design
- Enrollment
- 180 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: TelitaciceptTelitacicept
- Placebo Comparator: PlaceboPlacebo
Primary Outcome Measure
Change from baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) score at Week 24 [ Time Frame: Week 24 ]
Central Contacts
- Jeremy Sokolove617-655-6580
Locations (20)
Find similar trials in Los Angeles, CA
By research site
Related Studies
- Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)Recruiting · Alexion Pharmaceuticals, Inc. · Birmingham, Alabama
- A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia GravisPHASE2/PHASE3 · Recruiting · UCB Biopharma SRL · Chicago, Illinois
- Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Myasthenia GravisRecruiting · University of Missouri-Columbia · Fairway, Kansas
- A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia GravisPHASE2/PHASE3 · Recruiting · UCB Biopharma SRL · Denton, Texas